AstraZenca Reports Results of Fasenra (benralizumab) in P-lllb PONENTE Trial for Asthma
Shots:
- It is based on P-lllb PONENTE trial assessing Fasenra (benralizumab- 30mg) in adult patients with severe Asthma on high-dose ICS + LABA and long-term use of OCS therapy with or without additional asthma controller. This study included approx. 600 patients in EU- North America- South America- and Taiwan
- Results: 62% of patients achieved complete elimination of daily OCS use on 1EP and on the 2EP- 81% of patients achieved complete elimination or were able to reduce their daily OCS dose to 5mg or less when further reduction was not possible due to adrenal insufficiency
- Fasenra is mAb that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis. It is currently approved as an add-on maintenance treatment for severe eosinophilic asthma and is approved for self-administration in the US- EU and other countries
Ref: AstraZeneca | Image: Fox News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com